Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.

Histone deacetylase inhibitors induce thymidine phosphorylase expression in cultured breast cancer cell lines.

Puppin C, Puglisi F, Pandolfi M, Di Loreto C, Damante G.

Oncol Rep. 2011 Aug;26(2):309-14. doi: 10.3892/or.2011.1310. Epub 2011 May 20.

PMID:
21617864
2.

Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase.

Di Gennaro E, Piro G, Chianese MI, Franco R, Di Cintio A, Moccia T, Luciano A, de Ruggiero I, Bruzzese F, Avallone A, Arra C, Budillon A.

Br J Cancer. 2010 Nov 23;103(11):1680-91. doi: 10.1038/sj.bjc.6605969. Epub 2010 Nov 2.

3.

Modulation of Rad51, ERCC1, and thymidine phosphorylase by emodin result in synergistic cytotoxic effect in combination with capecitabine.

Ko JC, Tsai MS, Kuo YH, Chiu YF, Weng SH, Su YC, Lin YW.

Biochem Pharmacol. 2011 Mar 1;81(5):680-90. doi: 10.1016/j.bcp.2010.12.008. Epub 2010 Dec 17.

PMID:
21168393
4.

The predictive and therapeutic value of thymidine phosphorylase and dihydropyrimidine dehydrogenase in capecitabine (Xeloda)-based chemotherapy for head and neck cancer.

Saito K, Khan K, Yu SZ, Ronson S, Rhee J, Li G, Van Echo D, Suntharalingam M, O'Malley BW Jr, Li D.

Laryngoscope. 2009 Jan;119(1):82-8. doi: 10.1002/lary.20003.

PMID:
19117293
5.

Expression of thymidine phosphorylase and dihydropyrimidine dehydrogenase in human breast carcinoma cells and tissues.

Loo WT, Chow LW, Suzuki T, Ono K, Ishida T, Hirakawa H, Ohuchi N, Sasano H.

Anticancer Res. 2009 Jul;29(7):2525-30.

6.

Suppression of thymidine phosphorylase expression by promoter methylation in human cancer cells lacking enzyme activity.

Guarcello V, Blanquicett C, Naguib FN, El Kouni MH.

Cancer Chemother Pharmacol. 2008 Jun;62(1):85-96. Epub 2007 Sep 1.

PMID:
17805539
7.

Valproic acid potentiates the anticancer activity of capecitabine in vitro and in vivo in breast cancer models via induction of thymidine phosphorylase expression.

Terranova-Barberio M, Roca MS, Zotti AI, Leone A, Bruzzese F, Vitagliano C, Scogliamiglio G, Russo D, D'Angelo G, Franco R, Budillon A, Di Gennaro E.

Oncotarget. 2016 Feb 16;7(7):7715-31. doi: 10.18632/oncotarget.6802.

8.

Induction of thymidine phosphorylase in both irradiated and shielded, contralateral human U87MG glioma xenografts: implications for a dual modality treatment using capecitabine and irradiation.

Blanquicett C, Gillespie GY, Nabors LB, Miller CR, Bharara S, Buchsbaum DJ, Diasio RB, Johnson MR.

Mol Cancer Ther. 2002 Oct;1(12):1139-45.

9.

Evaluations of biomarkers associated with sensitivity to 5-fluorouracil and taxanes for recurrent/advanced breast cancer patients treated with capecitabine-based first-line chemotherapy.

Zhao HY, Huang H, Hu ZH, Huang Y, Lin SX, Tian Y, Lin TY.

Anticancer Drugs. 2012 Jun;23(5):534-42. doi: 10.1097/CAD.0b013e32834f7ef4.

PMID:
22481060
10.

Making capecitabine targeted therapy for breast cancer: which is the role of thymidine phosphorylase?

Bonotto M, Bozza C, Di Loreto C, Osa EO, Poletto E, Puglisi F.

Clin Breast Cancer. 2013 Jun;13(3):167-72. doi: 10.1016/j.clbc.2012.10.002. Epub 2012 Dec 5. Review.

PMID:
23218471
11.

Lidamycin up-regulates the expression of thymidine phosphorylase and enhances the effects of capecitabine on the growth and pulmonary metastases of murine breast carcinoma.

Zhang SH, Zhang H, He HW, Li L, Li XQ, Zhang YP, Shao RG.

Cancer Chemother Pharmacol. 2013 Oct;72(4):777-88. doi: 10.1007/s00280-013-2253-3. Epub 2013 Aug 23.

PMID:
23975242
12.

Neoadjuvant docetaxel and capecitabine and the use of thymidine phosphorylase as a predictive biomarker in breast cancer.

Layman RM, Thomas DG, Griffith KA, Smerage JB, Helvie MA, Roubidoux MA, Diehl KM, Newman LA, Sabel MS, Hayman JA, Pierce LJ, Hayes DF, Schott AF.

Clin Cancer Res. 2007 Jul 15;13(14):4092-7.

13.

Positive interaction between lapatinib and capecitabine in human breast cancer models: study of molecular determinants.

Chefrour M, Milano G, Formento P, Giacometti S, Denden A, Renée N, Iliadis A, Fischel JL, Ciccolini J.

Fundam Clin Pharmacol. 2012 Aug;26(4):530-7. doi: 10.1111/j.1472-8206.2011.00945.x. Epub 2011 May 30.

PMID:
21623901
14.

Inhibition of EGFR phosphorylation in a panel of human breast cancer cells correlates with synergistic interactions between gefitinib and 5'-DFUR, the bioactive metabolite of Xeloda.

Ait-Tihyaty M, Rachid Z, Mihalcioiu C, Jean-Claude BJ.

Breast Cancer Res Treat. 2012 May;133(1):217-26. doi: 10.1007/s10549-011-1756-z. Epub 2011 Sep 14.

PMID:
21915635
15.
16.

Phase II study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: up-regulation of thymidine phosphorylase.

Saif MW, Black G, Roy S, Bell D, Russo S, Eloubeidi MA, Steg A, Johnson MR, Zelterman D, Diasio RB.

Cancer J. 2007 Jul-Aug;13(4):247-56.

PMID:
17762760
17.

Inhibition of thymidine phosphorylase expression by using an HSP90 inhibitor potentiates the cytotoxic effect of cisplatin in non-small-cell lung cancer cells.

Weng SH, Tseng SC, Huang YC, Chen HJ, Lin YW.

Biochem Pharmacol. 2012 Jul 1;84(1):126-36. doi: 10.1016/j.bcp.2012.03.011. Epub 2012 Mar 27.

PMID:
22480737
18.

[Improved sensitivity of gastric carcinoma cells to fluorouracil-related drugs by transfection of thymidine phosphorylase gene].

Zhuo LJ, Gao MQ, Huang AM.

Zhonghua Bing Li Xue Za Zhi. 2011 May;40(5):330-3. Chinese.

PMID:
21756828
19.

Radiation recall phenomenon secondary to capecitabine: possible role of thymidine phosphorylase.

Saif MW, Black G, Johnson M, Russo S, Diasio R.

Cancer Chemother Pharmacol. 2006 Dec;58(6):771-5. Epub 2006 Mar 22.

PMID:
16552574
20.

Preoperative radiotherapy and concomitant capecitabine treatment induce thymidylate synthase and thymidine phosphorylase mRNAs in rectal carcinoma.

Kocakova I, Svoboda M, Kubosova K, Chrenko V, Roubalova E, Krejci E, Sefr R, Slampa P, Frgala T, Zaloudik J.

Neoplasma. 2007;54(5):447-53.

PMID:
17688376

Supplemental Content

Support Center